Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038531 | 0.94 | MBTD1 (0.54) | MBTD1L3MBTL1HRH3TSHRMEN1 | |
| SCHEMBL6038688 | 0.89 | RAB9A (0.48) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6038730 | 0.86 | KDM4E (0.47) | L3MBTL1HRH3KCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6039203 | 0.83 | MEN1 (0.56) | MBTD1L3MBTL1HRH3TSHRMEN1 | |
| SCHEMBL6038966 | 0.80 | LMNA (0.47) | TSHRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6038633 | 0.79 | KMT2A (0.46) | L3MBTL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6038473 | 0.79 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6038854 | 0.79 | MEN1 (0.47) | TSHRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6039178 | 0.78 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6039167 | 0.78 | MEN1 (0.58) | MBTD1L3MBTL1HRH3TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | MBTD1 3263/4885L3MBTL1 2666/4885HRH3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.